Details of Disease

General Information of Disease (ID: DISW25G5)

• Disease Name: Sickle-cell disorder
• Disease Class: 3A51: Sickle-cell disorder
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISW25G5: Sickle-cell disorder
• ICD Code:
  ICD-11: ICD-11: 3A51
  ICD-10: ICD-10: D57, D57.8
  ICD-9: ICD-9: 282.5, 282.6
  Expand ICD-9: 282.5,282.6

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Crizanlizumab	DMAHOVJ	Approved	Antibody	[1]
Nix-0699	DMOUSAQ	Approved	NA	[2]
Voxelotor	DMCS6M5	Approved	NA	[3]

This Disease is Treated as An Indication in 25 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CRL-8131	DMCIY7N	Phase 3	Small molecular drug	[4]
Inclacumab	DMXV94M	Phase 3	Monoclonal antibody	[5]
LentiGlobin	DMSCGM8	Phase 3	NA	[4]
Etavopivat	DMXOHYH	Phase 2/3	Small molecule	[6]
GBT021601	DMD3C21	Phase 2/3	Small molecule	[7]
PEG-bHb-CO	DMJ38X9	Phase 2/3	NA	[4]
ALXN1820	DMNZOJ3	Phase 2	antibody	[8]
Epeleuton	DMJ1YQ2	Phase 2	Small molecule	[9]
IMR-687	DM15MRZ	Phase 2	Small molecular drug	[10]
IW-1701	DM457XO	Phase 2	Small molecular drug	[11]
Pegylated carboxyhemoglobin	DMTRTGZ	Phase 2	NA	[12]
PF-4447943	DM81D4I	Phase 2	Small molecular drug	[4]
SelG2	DM1RDPO	Phase 2	NA	[13]
BIVV-003	DMT10TD	Phase 1/2	Cell therapy	[14]
CTX001	DM90XQC	Phase 1/2	Gene therapy	[15]
RVT-1801	DM0BZK0	Phase 1/2	Gene therapy	[16]
ASP8731	DM9RU1U	Phase 1	Small molecule	[17]
BCL11a shRNA	DMQ76B4	Phase 1	Short hairpin RNA	[18]
CSL-889	DM5ZOUS	Phase 1	Protein	[19]
GSK4172239	DM930LE	Phase 1	NA	[20]
NKTT-120	DMI7ZK3	Phase 1	Antibody	[21]
PF-07059013	DMSDVKK	Phase 1	Small molecule	[22]
PF-07209326	DM7YRAL	Phase 1	Small molecule	[23]
SAR445136	DMDZF6C	Phase 1	Cell therapy	[24]
TT-00920	DMP6G0P	Phase 1	Small molecule	[25]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT04662931) An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients. U.S. National Institutes of Health.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT05348915) An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial. U.S.National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04624659) An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS). U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT05632354) An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial. U.S.National Institutes of Health.
• [8] ClinicalTrials.gov (NCT05565092) A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease. U.S.National Institutes of Health.
• [9] ClinicalTrials.gov (NCT05861453) An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease. U.S.National Institutes of Health.
• [10] ClinicalTrials.gov (NCT03401112) A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-beta0 Thalassemia). U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT03285178) A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD). U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT01925001) Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis. U.S. National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals.
• [14] ClinicalTrials.gov (NCT03653247) A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease (PRECIZN-1). U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT03745287) A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT02186418) Gene Transfer for Patients With Sickle Cell Disease. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT05167526) A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP8731 in Healthy Adult Participants, Including an Assessment of a Food Effect. U.S.National Institutes of Health.
• [18] ClinicalTrials.gov (NCT03282656) Gene Transfer for Sickle Cell Disease. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT04285827) A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease. U.S.National Institutes of Health.
• [20] ClinicalTrials.gov (NCT05660265) A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D. U.S.National Institutes of Health.
• [21] ClinicalTrials.gov (NCT01783691) Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD). U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT04323124) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07059013 AND OPEN-LABEL ASSESSMENT OF FOOD AND FORMULATION ON PHARMACOKINETICS OF PF-07059013 IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
• [23] ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
• [24] ClinicalTrials.gov (NCT05145062) An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant. U.S.National Institutes of Health.
• [25] Clinical pipeline report, company report or official report of TransThera Biosciences